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ABSTRACT
RNA reagents of diverse lengths and structures,
unmodified or containing various chemical modifi-
cations are powerful tools of RNA interference and
microRNA technologies. These reagents which are
either delivered to cells using appropriate carriers or
are expressed in cells from suitable vectors often
cause unintended sequence-non-specific immune
responses besides triggering intended sequence-
specific silencing effects. This article reviews the
present state of knowledge regarding the cellular
sensors of foreign RNA, the signaling pathways
these sensors mobilize and shows which specific
features of the RNA reagents set the responsive
systems on alert. The representative examples of
toxic effects caused in the investigated cell lines
and tissues by the RNAs of specific types and
structures are collected and may be instructive for
further studies of sequence-non-specific responses
to foreign RNA in human cells.
THE LANDSCAPE OF CELLULAR TRANSCRIPTS
AND RNA-BINDING PROTEINS
To review the non-speciﬁc responses of human cells to
various RNA interference triggers and microRNA
regulators, we begin with a brief presentation of the
action scene on which both the sequence-speciﬁc silencing
and non-speciﬁc side eﬀects take place, and focus on the
cellular repertoire of the transcripts and RNA-binding
proteins named jointly the ribonome (1). The elements
of this complex system are either targeted by foreign
RNA or are implicated in generating the appropriate
cellular responses.
Recent studies show that most of the human genome is
transcribed (2), and only  1% is translated. Besides the
abundant RNAs such as rRNAs, tRNAs and snRNAs
a plethora of mature cellular transcripts include mRNA
variants from about 20500 human protein-coding genes
(3), and it is still diﬃcult to estimate the numbers of long
and short non-coding RNAs (ncRNAs). The long ncRNAs
encompass species overlapping with protein coding
transcripts, cis-antisense, bidirectional and intronic trans-
cripts (4), whereas short ncRNAs include microRNAs
(miRNAs), endogenous short interfering RNAs (siRNAs)
and PIWI-interacting RNAs (piRNAs) (5).
Considering the structural features of cellular RNAs
these also come in many varieties (6,7). The sense and
antisense transcripts from numerous genes or genomic
regions may form long stretches of double-stranded
structures in the cell nucleus but most of the nuclear and
cytoplasmic transcripts remain single-stranded. These
transcripts typically form intrinsic higher order structures,
which depending on their nature and stability, may or may
not interfere with normal cellular processes. For example,
short RNA hairpins containing stems composed of up to
10bp are very common RNA structures both in the
nucleus and cytoplasm and they are harmless to human
cells. On the other hand, hairpins that are excessively long
(8), very stable pseudoknots (9) and quadruplexes (10) are
less frequent and potentially harmful.
The cellular complement of RNA-binding proteins is
very rich in comparison to other protein superfamilies.
At least 2500 diﬀerent human proteins contain RNA-
binding domains (1) and among these proteins there are
already identiﬁed and yet unknown cellular sensors of
foreign RNA. The most commonly occurring domains
include: the RNA recognition motif (RRM) found in
about 2% of human proteins, and the K-homology
domain (KH) both recognizing primarily the single-
stranded RNA, and the double-stranded RNA-binding
domain (dsRBD) and zinc ﬁngers (ZnF) showing a high
aﬃnity to dsRNA fragments. These domains bind RNA in
a structure-dependent manner (11–13). For example, the
dsRBD binds any dsRNA provided the base-paired region
extends to at least 12bp and is not interrupted by too
many bulges or internal loops (13).
The dynamic associations of proteins containing RNA-
binding domains with cellular RNAs deﬁne all the steps of
the lifecycle of transcripts starting from their synthesis,
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and localization, to the stages at which transcripts
perform their functions, and are ﬁnally degraded (14).
The high functional diversity of RNA-binding proteins
contrasts with the much fewer number of diﬀerent types
of RNA-binding domains. To accompany the multitude
of transcripts in their cellular journey and participate in
their functions, these proteins have developed modular
structures in which the repeated RNA-binding domains
are often separated by peptide spacers of diverse lengths
(12). This structural organization enables the binding of
diﬀerent RNAs with diﬀerent aﬃnities and allows ﬁnding
the cognate transcripts in a crowded cellular milieu.
It is also becoming apparent that the issue of the cellular
localization of transcripts needs to be more appreciated
when considering the eﬃciency of various RNA-targeting
technologies and their side-eﬀects. This question is no
longer relevant to only a handful of mRNAs performing
specialized local functions in the polarized asymmetric cells
such asﬁbroblasts or neurons but mayapply to many other
mRNAs as well (15). What is very likely is the emerging
scenario in which mature transcripts after leaving a cell
nucleus are assembled together with ribosomal subunits
and translation factors into the large RNA granules that
are transported by motor proteins along cytoskeletal
elements to their destination sites (16). At these speciﬁc
sites the messages are translated, and targeted by endo-
genous or exogenous regulators of translation.
Human cells are also equipped with eﬃcient transcript
turnover and quality control systems designed to degrade
the products of excessive transcription, the by-products of
RNA processing, normal transcripts that ended their life-
cycle, and defective transcripts having impaired process-
ing, translation, folding or protein assembly (17). Along
with these systems the RNA interference (RNAi) pathway
exists and shares cellular resources with a functionally
relevant system of posttranscriptional regulation of gene
expression by miRNAs.
MicroRNA AND RNA INTERFERENCE
PATHWAYS AND THE CORRESPONDING
TECHNOLOGIES
At the beginning of this decade an entirely new level of
gene regulation by miRNAs was uncovered in the cells of
eukaryotic organisms (18–20). Since then more than 700
miRNAs have been identiﬁed in human cells (21) and it is
estimated that the majority of human protein coding genes
is under the control of these  20nt RNAs (22). The main
steps of miRNA biogenesis and activity as well as the sites
of potential intervention with the tools of RNAi and
miRNA technologies are shown in Figure 1. The
majority of the primary transcripts of human miRNA
genes (pri-miRNAs) are generated by RNA polymerase
II (23). The pri-miRNAs, which harbor a long stem and
loop structure are processed in the nucleus to shorter
hairpin precursors (pre-miRNAs) which are  60nt in
length. The nuclear processing enzyme is ribonuclease
Drosha (24) which forms together with the DGCR8
protein (25) the core of the Microprocessor complex
(26,27). Drosha which is the RNase III enzyme usually
leaves a 2nt overhang at the 30-end of pre-miRNA and
deﬁnes one end of mature miRNA. The pre-miRNA is
then exported to cytoplasm by Exportin-5/Ran-GTP
(28) where it is intercepted by the RISC loading complex
(RLC) composed of another RNase III enzyme Dicer,
TAR RNA binding protein (TRBP) and a member of
the argonaute protein family (AGO1–4). The pre-
miRNA cleavage by Dicer excises an imperfect duplex
from its hairpin stem and deﬁnes the other miRNA end.
The presence of structure imperfections within this duplex
facilitates the non-miRNA strand to be disposed from
the RLC to form an active miRISC complex (29).
The miRISC then uses the miRNA strand as a guide to
search for mRNAs having in their 30-UTR complementary
sequences to its seed region (30) and target mRNAs are
translationally inhibited or deadenylated and degraded.
The ﬁrst reagents of RNAi technology were developed
before the details of miRNA biogenesis were revealed.
The technology we use today has been ﬁne-tuned by
taking lessons from the more advanced knowledge of the
miRNA biogenesis process. The exogenous silencing
reagents enter the miRNA pathway at its diﬀerent stages
and take advantage of the same processing and efector
proteins to evoke a sequence-speciﬁc mRNA cleavage
(Figure 1). Although the process of RNAi can be
induced by the single-stranded siRNAs (ss-siRNAs)
(31–33) it is more eﬃciently triggered by  20bp siRNA
duplexes (ds-siRNAs) mimicking the cleavage products of
miRNA precursors by Drosha and Dicer, having typically
the 2nt 30-overhangs. The ds-siRNAs (34,35) and ss-
siRNAs (36) are also eﬀective in transcriptional gene
silencing (TGS) by targeting gene promoters. Longer
RNA duplexes (27–30bp) that have to be ﬁrst processed
by Dicer to generate siRNAs are also very eﬃcient RNAi
inducers (37–39). Synthetic RNA hairpins transfected to
cells were also shown to be potent RNAi triggers (40). The
vector-based RNAi triggers such as short hairpin RNAs
(shRNAs) (41,42) and long hairpin RNAs (lhRNAs) (43)
or pri-miRNA-based expression cassettes (sh-miRs) (44)
enter the miRNA biogenesis pathway prior to the Dicer or
Drosha processing steps, respectively, and confer the long-
lasting silencing eﬀects as compared to synthetic reagents.
The more recently developed miRNA technology
(Figure 1) is aimed at either blocking or overexpressing
cellular miRNAs for diﬀerent purposes. To downregulate
the overexpressed miRNAs, the antisense oligonucleotides
known as antimirs (45) or antagomirs (46,47) are used.
Another approach to inhibit the overexpressed miRNAs
is the use of miRNA sponges (48) or decoys (49,50) that
are either plasmid or viral vector-encoded mRNA
fragments designed to sequester the overproduced
miRNAs. In still another strategy, the abnormally
increased levels of speciﬁc miRNAs remain unchanged
but the antisense RNA oligomers named ‘target
protectors’ are used (51) to protect the miRNA binding
sites in the regulated mRNAs. On the other hand, in cases
of miRNA under-expression, such miRNA may be
transfected to cells either as an antisense strand of
siRNA-like duplex known as miRNA mimetic (52) or in
the form of synthetic pre-miRNA (40). Alternatively,
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vectors (53,54) in the way the shRNAs and sh-miRs
are expressed.
To be eﬀective, the RNAi triggers and miRNA
regulators have to ﬁrst enter the cell and reach their
targets. The nucleic acids delivery methods fall into two
major categories viral and non-viral. Among the non-viral
methods, the use of various synthetic and natural carriers
is very popular. Numerous positively charged carriers
have been shown to facilitate the crossing of a negatively
charged cellular membrane by the negatively charged
nucleic acids reagents. The major types of synthetic
carriers include cationic lipids, polymers and cell penetrat-
ing peptides that easily traverse a cellular membrane and
protect their cargo from rapid degradation by nucleases
(55,56). The cellular uptake of nucleic acids reagents
occurs via the natural portals of entry to cells by which
various macromolecules and particles are imported. This
process known as endocytosis includes a number of
diverse pathways and mechanisms (57,58) that may
deliver complexes of reagents and their carriers to
speciﬁc cellular compartments (59,60). A common theme
in these mechanisms is that cargo is internalized in
transport vesicles derived from fragments of the plasma
membrane. Cellular uptake of the frequently used cationic
lipid complexes with small RNA often referred to as
lipoplexes, is thought to occur via clathrin-mediated
endocytosis. The use of this transportation pathway
results in lipoplex localization in endosomes/lysosomes
as it was shown for DNA complexes with cationic lipids
(61). To elicit its activity, the small RNA has to be
released to cytosol from the endosomal trap. The
process of endosomal escape being a critical barrier of
eﬀective siRNA delivery (59) is facilitated by endosome
acidiﬁcation that occurs as endosome matures into a
lysosome (62). Also, the ion pair interactions between
carrier cationic lipids and anionic lipids in endosome ulti-
mately destabilize the endosomal membrane and facilitate
the endosome escape by lipoplex (55). Then, in the low
pH endosome environment small RNAs also dissociate
Figure 1. The steps of miRNA biogenesis and functioning as well as sites of intervention with the tools of RNAi and miRNA technologies.
The miRNA biogenesis includes: 1, transcription of most of the miRNA genes by RNA Pol II to produce the pri-miRNA precursor; 2, nuclear
processing of pri-miRNA by the Microprocessor complex, to generate the 50–70nt long hairpin-shaped pre-miRNA; 3, the export of pre-miRNA to
cytoplasm guided by the Exportin-5/Ran-GTP complex; 4, the pre-miRNA takeover by RISC loading complex; 5, excision of the imperfect miRNA/
antimiRNA duplex from the pre-miRNA; 6, the antimiRNA strand release resulting in the formation of active miRISC, and ﬁnally ﬁnding the target
mRNA by the miRISC and binding to its 30UTR with either a partial or complete base complementarity leading, respectively, to 7, mRNA
translational inhibition or 8, mRNA deadenylation and degradation. RNAi and miRNA technology essentials delivered either by transfection
(ds-siRNA, ss-siRNA, shRNA, pre-miRNA, promoter-speciﬁc siRNA, target protector, antimiR, miRNA sponge and mimetic) or released from
expression vectors (shRNA, sh-miR, pri-miRNA and pre-miRNA).
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RNAi pathway. The delivery issues have been discussed in
more detail in several excellent recent reviews (63–65).
Both the RNAi and miRNA technologies are widely
used in basic research to study the functions of speciﬁc
proteins and miRNAs. These technologies may also
provide new therapeutics, rationally designed by taking
advantage of the human genome sequence knowledge.
On the way to achieving this objective several obstacles
have to be overcome (66) and avoiding or reducing the
toxic eﬀects caused by foreign RNA belongs to the most
serious challenges (67–69).
CELLULAR SENSORS AND RESPONDERS TO
FOREIGN RNA
The toxicity of reagents of RNAi and miRNA
technologies may have diﬀerent sources: (i) saturation of
cellular proteins involved in RNAi and miRNA pathways
(70,71), (ii) sequence-speciﬁc targeting of other,
unintended transcripts (oﬀ-target eﬀect) (72,73) and (iii)
sequence-non-speciﬁc activation of cellular sensors of
foreign RNA and their downstream eﬀects leading to
interferon (IFN) induction and cell death (67,74). The
latter eﬀect depends mostly on the length, structure,
chemical modiﬁcation and cellular localization of the
reagent rather than on its sequence features. The
question of cellular responses to foreign RNA was
addressed a long time before the appearance of RNAi
and microRNA technologies in the context of viral
infections. The ﬁrst identiﬁed cellular sensors of foreign
RNA were the IFN-inducible dsRNA-activated protein
kinase (PKR) (75) and 20-50-oligoadenylate synthetase
(OAS) (76). Later, the ﬁrst RNA-responsive toll-like
receptor 3 (TLR3) was described (77), and the main
components of the downstream signaling pathways from
these RNA sensors were identiﬁed (Figure 2).
PKR
This 68kDa protein is composed of the C-terminal kinase
domain (KD) and N-terminal dsRNA-binding domain
(dsRBD) containing two dsRNA binding motifs
(dsRBMs), each capable of binding the 11–13bp RNA
(78–81). The protein is localized predominantly in the
cytoplasm associated with ribosomes (82), but its
fraction is also found in the cell nucleus (83). PKR is
perhaps the best studied RNA sensor in the aspect of
the activation mechanism and induced downstream
eﬀects. It has been established that upon dsRNA
binding protein dimerization and autophosphorylation
occurs and is followed by the phosphorylation of
a-subunit of a translation initiation factor eIF2 (79,84)
and IkB protein (85). This results in the general inhibition
of protein synthesis and nuclear translocation of NF-kB
respectively (Figure 2). PKR is also involved in the regu-
lation of other signaling pathways. One of these pathways
involves the p38, MAP/INK and STAT1 proteins leading
to the enhanced transcription of IFN-stimulated genes,
and the other pathway results in the activation of
transcription factors ATF2 and c-Jun leading to the
expression of inﬂammatory cytokines. Recently, the
PKR was shown to be engaged in the modulation of tran-
scription via interaction with RNA helicase A (RHA) (86).
It was shown by simple tests such as ﬁlter-binding, gel
retardation and kinase assay that the kinase domain of
recombinant PKR is optimally activated by long  80bp
dsRNAs (81) and that the length of  30bp is the lower
limit of dsRNA that activates PKR (81,87,88). It was also
reported that even shorter dsRNAs containing bulges and
internal loops are able to activate the enzyme, suggesting
the importance of RNA structure in this activation
process (89,90). For example the RNA composed of the
16bp hairpin stem ﬂanked by 10–15nt single-stranded
tails was shown to activate PKR (91). Moreover, it has
been demonstrated that PKR can be activated by rela-
tively unstructured transcripts containing 50-triphosphate,
recognized as a pathogen-associated molecular pattern
(PAMP) (92). In a more relevant cell culture study that
used T98G cells and PKR kinase activity assay it was
shown that the transfection of 21bp siRNA activates
PKR in a concentration-dependent manner (93). On the
other hand, a microarray study (94) demonstrated that the
level of PKR mRNA was not inﬂuenced by 19bp siRNA
transfection to HEK293 and HeLa S3 cells but it was
up-regulated after 27bp siRNA transfection. Taking into
account that up-regulation of the PKR mRNA may result
from the secondary eﬀect of its activation by IFN, we
consider the results of protein phosphorylation tests to
be more relevant.
OAS
Three members of the OAS family: OAS1 (40kDa), OAS2
(69kDa) and OAS3 (100kDa) are products of diﬀerent
genes and contain one, two and three OAS units, respec-
tively, encoded by ﬁve translated exons (95,96). The fourth
member the OASL (OAS-like IFN-induced protein) is
devoid of the 20-50 OAS catalytic activity. The OAS
enzymes contain two non-contiguous domains that
together form a platform for dsRNA binding (97). The
three forms of OAS are associated with diﬀerent
subcellular fractions, including membranes, cytoplasm
and nucleus. The activated OAS converts ATP to the 20-
50-oligoadenylates of various sizes and these activate
RNase L (76,98) which is an endonuclease involved in
RNA degradation (Figure 2). This sequence of events
leads to the general inhibition of protein synthesis and
ultimately to cell apoptosis (99). OAS activation takes
place in human cells upon strong IFN induction after a
viral infection and among the known OAS inducers are
the TAR RNA of HIV-1 (100) and VAI RNA of
adenoviruses (101). Like other IFN-inducible genes, the
promoter regions of OAS1, OAS2 and OAS3 contain an
IFN-stimulated response element (ISRE). The informa-
tion regarding OAS activating RNAs that was gathered
prior to the appearance of RNAi technology is inconsis-
tent. In an earlier study using 20-50-oligo(A) syntethase and
protein kinase assays in HeLa cell extract the poly (I:C)
of the length >40bp showed an activatory eﬀect but
>65bp RNAs were required for maximum activity
(102). Two decades later using the same assay the length
4 Nucleic AcidsResearch, 2010,Vol. 38,No. 1limit of dsRNA, that activated recombinant OAS2, was
shown to be lower >15bp (103). This discrepancy can be
explained by the diﬀerences in the experimental conditions
used in these two studies. The structure imperfections
within dsRNA were shown to inhibit the activation of
OAS proteins (102). In a more relevant RNAi experiment
in which the silencing of GAPDH was evaluated by
microarrays, the 21bp siRNAs were shown to activate
OAS2 and to a lower extent OAS1 and OAS3 in a
concentration-dependent manner (93).
TLRs 3,7,8
The TLR3 belongs to a family of proteins composed of
11 members that recognize diﬀerent PAMPs (104).
The cellular role of 116kDa TLR3 is to detect viral
dsRNA either in the cytoplasm or at the cell surface
and activate the pathways involved in the transcrip-
tional response (77,105). The RNA recognizing activity
resides in the leucine-rich region (LRR) projecting
towards the cell exterior (ﬁbroblasts, macrophages)
or endosome interior (CD11c cells), while the Toll/IL-1
receptor domain (TIR) that is the signaling domain
projects towards the cytoplasm. TLR3 activates tran-
scription factors IRF3, NFkB and ATF2-c-Jun via
the TRIF adaptor protein and promotes the expression
of IFNb and pro-inﬂammatory cytokines such as IL-6
and TNFa (106,107). It has been shown that the
endothelial cell surface TLR3 is activated in vivo by
exogenous siRNA of at least 21nt in length, leading
to the production of IFNg and IL-12 cytokines (108).
Among the known TLR3 inducers is synthetic poly(I:C)
frequently used as a positive control in experiments
testing cell responses to natural activating dsRNAs or
exogenous RNAi triggers. The TLR3 induction simi-
larly to the activation of the earlier discussed dsRNA
sensors is sequence independent. In contrast, the toll-like-
receptors TLR7 and TLR8 which are presumably
expressed in the endosomes of immune cells, recognize
the RNAs trapped in these vesicles in a sequence-
dependent manner (109). It has been shown for
example, that these receptors are sensitive to speciﬁc
sequence motifs that are U- and G-rich (110–112). It
was also demonstrated that the presence of ribose
backbone and multiple uridine residues in close
proximity were the elements required for ssRNA recog-
nition by TLR7 (113). The TLR7 and TLR8 primarily
bind the single-stranded viral RNA but have also
the potential to recognize short dsRNAs. These recep-
tors were shown to be activated by both the siRNA
duplexes and single-stranded siRNAs (74,114–115).
The TLR7 and TLR8 signal via the MyD88 adaptor
(Figure 2). Depending on the cell type and TLRs
expressed their signals are transmitted either to the
IRF5, IRF7 or to NF-kB transcription factors, responsi-
ble for the upregulation of IFNa and inﬂammatory
cytokines.
RIG-I, LGP2, MDA5
More recently, three diﬀerent PAMP helicases: the
retinoic acid inducible gene I (RIG-I) (116), as well as
the LGP2 (117) and melanoma diﬀerentiation associated
gene-5 (MDA5) (118) also known as RIG-I like helicases
(RLHs) have been shown to be the primary cytoplasmic
sensors of foreign RNA in human cells. The RIG-I and
MDA5 contain at their N-terminus two caspase
recruitment domains (CARD) followed by a DExD/H
Figure 2. Cellular sensors and responders to dsRNA and ssRNA. After the activation of cytoplasmic (MDA5, RIG-I, PKR, OAS1-3) and
endosomal (TLR3, 7, 8) sensors, a signal is transduced via speciﬁc adaptor proteins to transcription factors that stimulate proinﬂammatory cytokines
and IFN production. TLR3 localization denoted by asterisk is cell type dependent. Endosomal TLR7/8 are expressed mainly in the immune system
cells.
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(CTD) involved in RNA recognition (119–121). LGP2
lacking the CARD domains exhibits no signaling capabil-
ity, but it can negatively regulate the signaling of RIG-I or
enhance the response of MDA5 to poly (I:C) (122,123).
After the CARD domains of RIG-I and MDA5 are
activated they speciﬁcally interact with another CARD-
containing adaptor protein, localized on the
mitochondrial membrane and named either IPS-1 (IFNb
promoter stimulator 1) (124), or MAVS (mitochondrial
antiviral signaling) (125), or VISA (virus-induced signal-
ing adaptor) (126) or Cardif (127). The signal is transmit-
ted further to transcription factors IRF3, IRF5 and IRF7
that stimulate cytokine and IFN production (128,129)
(Figure 2). Upon dsRNA recognition the RIG-I and
MDA5 also activate the transcription factor NFk-B,
that mounts a cellular response by inducing a synthesis
of proinﬂammatory cytokines and type 1 IFNs (123).
RIG-I and MDA5 expression is IFN-inducible and is
rapidly upregulated following the IFN response initiation.
The RIG-I and MDA5 helicases were shown to be
sensitive to such features of dsRNA as its length, end-
structure and phosphorylation status. RIG-I and MDA5
selectively recognize short and long dsRNAs, respectively
(130). The full activation of RIG-I requires the blunt-
ended dsRNA containing triphosphate at the 50-end
(131–133), whereas MDA5 is activated by dsRNA
lacking the 50-triphosphate. The length of the blunt-
ended dsRNA that activates RIG-I is >20bp (131),
whereas the lower length limit of MDA5 activating
dsRNA still needs to be determined. The MDA5 and
LGP2 might also recognize the blunt ends of dsRNA
(121). RNAs containing 30 overhangs at the
50-triphosphate end suppress RIG-I activity and any 50
overhang at the 50-triphosphate end abolishes the
activity. These results are consistent with a previous
report which showed that the 21–23bp RNA duplexes
containing the 2nt 30 overhangs bind RIG-I but do not
induce its helicase activity (134). Several studies have
reported the activation of RIG-I by ssRNAs bearing
50-triphosphates (120,135–138). However, a recent study
demonstrated that ssRNA is not a ligand for RIG-I. This
discrepancy could be explained by the fact that all
previous studies used RNAs from in vitro transcrip-
tion with T7 RNA polymerase which were likely
contaminated by dsRNA species (131). It was also
recently shown that the RIG-I is an RNA-speciﬁc
translocase working either on dsRNA or RNA–DNA
duplex (139).
The ﬁrst-line cellular sensors of foreign RNA pre-
sented brieﬂy above have been identiﬁed using diﬀerent
approaches during more than three decades of research.
Notable progress in understanding the molecular basis of
RNA toxicity of this kind which has been achieved in this
decade has beneﬁted considerably from its importance for
today’s rapidly developing RNAi technology. In the next
section, we will present the selected results of these eﬀorts
and discuss what is known about cellular responses to
various types of reagents used by the RNAi and miRNA
technologies.
SEQUENCE-NON-SPECIFIC RESPONSES
INDUCED BY RNAi TRIGGERS AND
MicroRNA REGULATORS
Early attempts to study RNA interference in human cells
turned out to be unsuccessful due to the strong toxicity of
long dsRNAs resulting in cell death from IFN activation
(140,141). The discovery that short RNA duplexes
(siRNA) having the 2nt 30-overhangs that resemble
Dicer cleavage products could abrogate the toxic eﬀects
(142) gave rise to widespread applications of RNAi tech-
nology in mammalian systems. Thousands of diﬀerent
siRNA duplexes have been tested for the silencing
of human genes and rules of how to design the eﬀective
siRNAs have been published (143–145) and are avail-
able in the web sites of academic institutions and commer-
cial companies (http://jura.wi.mit.edu/bioc/siRNAext/,
http://katahdin.cshl.org:9331/RNAi_web/, https://
rnaidesigner.invitrogen.com/sirna/, www.ambion.com/
techlib/misc/siRNA_ﬁnder.html, http://bioinfo.clontech
.com/rnaidesigner/, http://www.dharmacon.com/
DesignCenter/). Yet, the toxicity issue was continuously
addressed as many siRNAs still triggered the sequence-
non-speciﬁc responses which were dependent on siRNA
length, structure, speciﬁc sequence content and concentra-
tion (Supplementary Table S1).
siRNAs
It has been demonstrated that short 19bp siRNAs do not
activate the PKR and TLR3 and do not show IFN
response even when used at high 100nM concentration
(94). The 21bp siRNAs were toxic in HeLa S3 cells at
100nM, whereas the toxicity of 23bp siRNAs was
observed already at 10nM (94). The transfection of
21bp siRNAs to T98G cells resulted in the dose-
dependent upregulation of STAT1 expression, as
detected by Western blot and semi-quantitative RT–
PCR analysis (93). The authors have also shown that
several IFN-stimulated genes (ISGs) were activated by
21bp siRNA in RCC1 cells (93). Some ISGs were
activated even at the 10nM concentration (OAS2,
OAS3, IFITM1, IFITM2), whereas others at higher
concentrations (OAS1). Among the immunostimulatory
sequences found in siRNAs were the GUCCUUCAA
(111), UGUGU (112), UGGC (73) and GU (113). These
sequences were shown to activate endosomal TLR7/8
sensors. This type of immunostimulation was abrogated
when naked siRNAs were delivered by electroporation,
skipping the endosomal acidiﬁcation and maturation,
required for siRNA recognition by TLR7/8 (115). These
observations are in accordance with a notion that
increased siRNA length and concentration are immuno-
stimulatory factors. However, speciﬁc sequences and other
factors may inﬂuence the relationship between siRNA
length, structure, concentration and toxicity.
The unmodiﬁed siRNAs work well in cell culture but
for in vivo applications they need to have a higher stability
which can be achieved by chemical modiﬁcation.
Again, numerous modiﬁcation sites and chemistries were
tested and some recommendations as to what types of
modiﬁcations may be introduced to diﬀerent siRNA
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cessful applications used chemistries that resemble natu-
rally occurring modiﬁcations such as 20-O-methyl RNA
(20-O-Me), 20-deoxy. The modiﬁcation of only one
siRNA strand (sense strand) was shown to be suﬃcient
to block the immunostimulatory potential of the duplex
and to minimize the risk for attenuating RNAi (149,150).
It was reported that 20-O-Me substitutions, in the selected
guanosine or uridine residues of synthetic siRNAs may be
suﬃcient to prevent immune activation (148,150–153).
However, the activation of TLR3 on the surface of
vascular endothelial cells by naked siRNA was not
inhibited by 20-O-Me modiﬁcation (109). The eﬀects of
20-deoxy (20-H) and 20-ﬂuoro (20-F) nucleotides on the
immunostimulatory activity of siRNA are diﬃcult to
explain and depend on the siRNA sequence and the
number and positions of the modiﬁed nucleotides (67).
Locked nucleic acids (LNAs) are known to enhance the
stability of siRNAs and do not have a negative impact on
RNAi activity (145,154). Also, diﬀerent siRNA variants
such as small internally segmented interfering RNA
(sisiRNA) (155) and siRNA with short sticky overhangs
(ssiRNA) (156) were successfully used oﬀering several
advantages, e.g. increased strand speciﬁcity and eﬃciency
of silencing.
Dicer-substrate siRNAs
The RNA duplexes known as Dicer-substrate siRNAs
were demonstrated to be eﬃcient RNAi triggers that
were active at lower concentrations than typical siRNAs
(39). The >23bp dsRNAs used at 10–100nM were shown
to mount an IFN response in a cell type-dependent
manner (94). For example, toxic eﬀects were observed in
MCF7 cells whereas HEK293 were found insensitive. The
results of another study are in line with the above
observations and show that 25–30bp siRNAs neither
activate the PKR nor induce an IFN response in
HEK293 cells (39). These results emphasize how impor-
tant is the right choice of cell lines used for in vitro toxicity
studies.
The Dicer-substrate siRNAs activated also the p56
protein encoded by the IFIT1 gene and resulted in IRF-
3 activation and enhanced IFN production (134,157). It
was also shown that blunt-ended siRNAs ranging from
21–27nt in length activated the IFN system via RIG-I
helicase (134) and the introduction of overhangs
(DNA) reduced RIG-I activity. The chemical
modiﬁcations of 47bp dsRNA such as 20-deoxyuridine
(20dU), 4-thiouridine (s4U), and 2-thiouridine (s2U)
abrogated its recognition by PKR (92).
ss-siRNAs
With regard to the single-stranded RNAi inducers, several
studies have shown that it is possible to skip the ds-siRNA
stage of RNA interference and assembly RISC using only
the antisense siRNA strand (31–33). The ‘guide strand
siRNAs’ were, however, less eﬀective and required about
10–100 times higher concentrations to achieve silencing
eﬀects comparable to those of ds-siRNAs (31–33). The
use of ss-siRNAs that formed partially complementary
strands (158) and ss-siRNAs with boranophosphate
modiﬁcations (146) substantially improved their silencing
eﬃciency which was likely due to the more eﬃcient for-
mation of active RISC. In spite of that the importance
of ss-siRNAs for RNAi technology is much lower than
that of ds-siRNAs. The ss-siRNAs containing immuno-
stimulatory sequence motifs were shown to be more
toxic than their ds-siRNA counterparts and the replace-
ment of the 20-hydroxyl of uridine residues in ss-siRNA
with either 20-F, or 20-H, or 20-O-Me groups abrogated the
activation of TLR7 and TLR8 (110,112,152). Finally, the
ss-siRNAs bearing 50-triphosphates synthesized by phage
polymerase were earlier thought to be immunostimulatory
by the activation of the RIG-I pathway (134–136).
However, according to a recent report the ssRNA is not
suﬃcient to support the recognition of 50-triphosphate by
RIG-I as was earlier explained in section Cellular sensors
and responders to foreign RNA (131).
shRNAs
The shRNAs expressed in cells from Pol III promoters
typically H1 promoter of RNase P or U6 snRNA
promoter are the most commonly used alternatives to
siRNAs when longer-lasting silencing eﬀects are required
(41,42,159–163). The price paid for the prolonged expres-
sion may be a lower silencing speciﬁcity caused by the
length heterogeneity of siRNAs excised from shRNAs
by Dicer (our unpublished data). The shRNAs themselves
have a heterogenous 30-end (the U-tail length) caused by
the nature of the Pol III transcription termination signal
(usually 4–6T residues) (164). The shRNA vectors are
introduced to cells either by transfection with cationic
lipids or within non-integrating adenoviral vectors (AV),
adeno-associated vectors (AAV) or lentiviral vectors
having the ability to integrate with genome. In the less
frequently used approach, shRNAs are delivered to cells
as synthetic molecules via transfection (40,42,159). It was
reported that transcripts synthesized by T7 phage
polymerase containing 50-triphosphates induce strong
immune responses (135,165); however, it is possible to
overcome this problem by transcript 50-end modiﬁcation
(166). The shRNA expression is considered more toxic to
cells than siRNA delivery and the overall toxicity may be
split into eﬀects resulting from vector DNA and eﬀects
caused by transcripts usually expressed at high levels.
The DNA-related eﬀects include cell responses to the
delivery of non-methylated DNA sequences. It is known
that introducing foreign DNA that contains non-
methylated CpG sequences to human cells stimulates a
strong immune response (167), and that such sequences
are recognized by TLR9 (168) which is localized like
TLR7 and TLR8 on endosomes. Another known
cytoplasmic DNA sensor is the DNA-dependent activator
of IFN-regulatory factors (DAI; DLM-1/ZBP1) which
activates the IFN type-1 production (169). Also, the AA
dinucleotide present near the transcription start site of
the U6 promoter was reported to induce OAS and other
IFN-responsive genes (170). The prototypical shRNA
designs contain either a 19bp or 29bp stem and loop of
various sizes and sequences (171,172). Their long and fully
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responses (173,174). Another serious problem results
from the usually high level of shRNA expression. The
abundance of transcripts which resemble the natural pre-
miRNAs was shown to overload the endogenous
pathways of miRNA biogenesis and be lethal (175). The
most sensitive to saturation in vivo is the step of the
Exportin-5-mediated transport of pre-miRNA from
nucleus to cytoplasm (71,175). Other studies also
reported the accumulation of miRNA precursors in cells
expressing high levels of shRNAs (173). Among the ways
to reduce such toxic eﬀects is the use of the lowest eﬀective
doses of shRNA expressing vector (41,174,176) and less
eﬃcient or regulated promoters (160,177). Another way
to diminish the immune responses caused by the long
stretch of regular dsRNA in the shRNA hairpin stem is
to introduce irregularities into this structure to resemble
more the natural pre-miRNAs (178). The toxicity of
shRNAs is also cell type dependent and according to
our experience the transfection of plasmid vectors
coding diﬀerent shRNAs (complexed with Lipofectamine
2000) into human ﬁbroblasts results in strong toxicity
and cell death, whereas the same constructs are non-
toxic to HeLa and HEK293 cells (M. Olejniczak et al.,
unpublished data).
sh-miRs
As not all disadvantages of the shRNA constructs could
be eliminated by simple means, the second generation of
siRNA expressing vectors was developed (44,179,180).
The sh-miRs mimic the pri-miRNAs, are expressed from
either Pol II or Pol III promoters and siRNAs are
expressed typically at lower levels which do not cause sat-
uration problems (161,181). The pri-miRNA-30 is the
most often used shuttle for siRNA expression (44,178)
known to abrogate OAS1 induction and cell toxicity
caused by the use of the shRNA vector (182). It would
be wise to test more of such pri-miRNA shuttles for the
eﬃciency and speciﬁcity of siRNA excision and subject
them to more rigorous toxicity testing.
miRNA delivery
Similar vector-based approaches may be used in miRNA
technology to overexpress speciﬁc miRNAs for research
or therapeutic purposes. The only diﬀerence is that the
miRNA expression cassettes are the wild-type pri-
miRNA sequence fragments of suﬃcient length to be eﬃ-
ciently processed in cells by the Microprocessor complex.
From the perspective of DNA-induced toxicity the
miRNA expressing systems, although not reported to be
tested in this respect, will suﬀer from the same limitations
as the siRNA expressing systems do. However, the pro-
cessed transcripts will be recognized by the cell as self since
they have identical sequences and structures as the corre-
sponding host transcripts. Another approach used to
deliver miRNAs to cells is to transfect cells with miRNA
mimetics, that are the 21–23bp double-stranded RNAs,
mimicking natural Drosha and Dicer products.
However, reports describing the applications of these syn-
thetic miRNA regulators (47–54,183–185) do not provide
any information regarding their sequence-non-speciﬁc
side-eﬀects (Supplementary Table S1).
miRNA inhibition
Of the reagents used to inhibit the overexpressed miRNAs
the antimirs are most frequently used. These single-
stranded antisense reagents that inhibit the RISC-bound
miRNAs (45) diﬀer in their length ranging from 16nt
(186) to 31nt (183,187). To increase their nuclease resis-
tance and the stability of their interactions with target
miRNAs the antimirs were subjected to various chemical
modiﬁcations. The most eﬃcient turned out to be the
ribose 20-hydroxyl substitution with one of the following:
the 20-O-Me, 20-O-metoksyetylo (20-MOE), 20-F or the use
of LNA, morpholino or phosphorothio (PS) chemistries
(54,183,188,189). The stability of the miRNA-antimir
interaction was strongly enhanced after extending the
antimir sequence with the ﬂanks forming a double-
stranded structure (190). Such antimirs were shown to
be functional at sub-nanomolar concentrations. For
in vivo applications, the cholesterol-conjugated and thio-
modiﬁed antimirs were successfully used (47,191). Certain
types of chemical modiﬁcations (20-O-Me-PS and 20-F-PS)
were shown to be toxic to cells when the antisense reagents
were used at high 100nM concentrations (188). According
to these authors, it was impossible to transfect by
lipofection >500nM antisense oligonucleotides of any
chemistry without inducing non-speciﬁc toxicity (188).
Taken together, still very little is known about the
toxicity of various reagents used by miRNA technology.
Yet, the relevant knowledge may be gained from more
numerous applications of the RNAi and antisense
technologies that use reagents of similar types and
lengths and which are stabilized with the same or similar
chemistries. One general conclusion that could be drawn
from these studies is that RNAs recognized by cells as self
(that resemble cellular transcripts in terms of structure and
localization) are rather tolerated, while those recognized
as foreign induce various responses depending on their
structural features, the way they entered the cell and the
cellular compartment they localize (128,134,192).
TESTING NON-SPECIFIC CELLULAR RESPONSES
TO FOREIGN RNA
Like viral invasion, cell transfection with RNAi or
miRNA reagent often results in the increased expression
levels of primary sensors of non-self RNA and other
proteins of the innate immune system. The increased
levels of proteins have typically their source in upregulated
transcripts. Thus, the predominant part of a known
system of sensors and responders to foreign RNA can
be analyzed for its activation using simple tests detecting
changes in RNA or protein levels such as RT–PCR or
Western blot. By now, the most frequently used tests
rely on the measurement of systemic cytokine and type-1
IFN release into the blood of treated animals, supported
by cytokine release assays from primary immune cell
cultures in vitro (67,68). A survey of relevant literature
shows, however, that the question of the activation of
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regulators is rarely addressed in a comprehensive way,
some studies address it only fragmentarily and most
studies do not address it at all (Supplementary Table
S1). This situation will likely change with the increased
number of in vivo applications of the RNAi and miRNA
technologies in which the safety issues need to be
thoroughly considered.
The common theme is also the misuse of tests for
immune response activation. Examples of their typical
misuse include: analyses of inappropriate cell lines which
either do not represent properly the target tissue, are
hardly immunostimulatory or both, analyses of one or a
few sensors and/or responders only, often not the right
ones and not in the right time, as recently discussed in
(67,193,194).
While testing non-speciﬁc cellular responses to foreign
RNA one should also carefully analyze the eﬀect caused
by the delivery system itself. It has been shown with
the use of microarrays that both Lipofectin and
Oligofectamine altered the expression of many genes in
human A431 epithelial cells (195). The aﬀected genes are
functionally involved in various cellular processes,
including cell proliferation, diﬀerentiation and apoptosis.
Another study demonstrated that Lipofectamine 2000 is
toxic to the HeLa and IGROV-1 cells both alone and after
complexation with diﬀerent siRNAs into lipoplex particles
(196). It has been also shown that the transfection of
human blood cells with Lipofectamine or polylysine
complexes with siRNA results in inﬂammatory cytokine
release, whereas siRNA encapsulated with stable nucleic
acid-lipid particles (SNALPs) or complexed with
polyethyleneimine (PEI) induce a response dominated by
IFNa secretion (111). The issue of carrier toxicity earlier
ignored or marginalized is now seriously taken into
account and carriers such as Lipofectamine
TM LTX are
oﬀered to meet the RNAi community expectations for an
eﬃcient and safe carrier.
The identiﬁed sources of sequence-non-speciﬁc toxic
eﬀects presented and commented in this and previous
sections gave rise to a set of guidelines that may help to
use the RNAi technology more safely. These guidelines
referring mainly to the diﬀerent features of RNAi
reagents are listed below:
siRNA sequence – avoid the immunostimulatory
sequences such as GU, UGGC, UGUGU, GUCCU
UCAA that activate TLR7/8,
siRNA structure – avoid blunt ends known to activate
RIG-I and MDA5 helicases and terminal
50-triphosphates activating RIG-I, make 2nt 30
overhangs for optimum activity,
siRNA length – use siRNAs of standard length 20–22nt
resembling the length of miRNA/miRNA* duplexes,
or not much longer Dicer-substrate siRNAs devoid
of blunt ends,
siRNA modiﬁcation – select chemical modiﬁcation
types known to be eﬃcient and safe, e.g. 20-O-Me,
20-deoxy, LNA,
siRNA concentration – use the lowest eﬀective con-
centrations/doses of siRNAs as the strength and
scale of toxic side-eﬀects clearly depend on siRNA
concentration,
siRNA delivery – use carriers that do not cause by them-
selves large changes in gene expression in target cells
and do not activate immune responses,
shRNA – avoid unmethylated CpG sequences activating
TLR9, design the shRNA structure to resemble the
pre-miR structure, use weak tRNA or H1 promoter,
sh-miR – use pre-miRNA ﬂanking sequences of suﬃcient
length to ensure Drosha processing occurs at natural
sites and use weaker Pol II promoters, sequence and
structure features as for shRNA,
target cells – while planning in vitro toxicity tests keep in
mind that some cells, e.g. MCF7, HeLa S3, PBMC are
more sensitive and some other, e.g. HEK293, HeLa
are less,
toxicity test – besides testing for IFNs and cytokines
levels the cellular pathways leading to toxicity,
including the primary RNA sensors and responders,
should be identiﬁed (Figure 2).
SEARCH FOR OTHER RNA SENSORS AND IMMUNE
RESPONDERS USING TRANSCRIPTOMICS AND
PROTEOMICS APPROACHES
To gain a more complete insight into the changes in gene
expression that occur upon the delivery of RNAi triggers,
miRNA mimetics and miRNA inhibitors functional
genomics and proteomics approaches were used in
several studies. These eﬀorts were primarily aimed at
revealing the scale of sequence-speciﬁc target-oﬀ eﬀects
in various RNAi applications (72,73) and identifying mes-
senger RNAs and proteins regulated by speciﬁc miRNAs
(197) rather than on ﬁnding new sequence-non-speciﬁc
sensors and responders to foreign RNA. In spite of that,
in several studies the latter aspect was also investigated.
For example, the microarray analysis of cellular
transcripts after the 27bp siRNA transfection resulted in
the identiﬁcation of immunosensitive cells (MCF7, HeLa
S3) mounting stronger innate immunity and less sensitive
cells (HEK293, HeLa) (94). In HeLa S3 cells, the Dicer-
substrate siRNA induced the expression of more than 300
genes that included transcripts associated with the detec-
tion of foreign RNA as well as IFN and apoptotic signal-
ing pathways (the TLR3, RIG-I, MDA5, IFITM1, OAS3,
OASL, STAT1-2). In other studies, the toxic sequence
motif UGGC was identiﬁed in siRNAs (73), and
shRNAs expressed from the U6 promoter were shown
to be more toxic than those expressed from the H1
promoter (198).
The ﬁrst proteomic analysis of HeLa cells transfected
with the miR-1 mimetic revealed a down-regulation of 12
out of 504 investigated proteins (199). The analysis was
performed using stable isotope labeling by the amino acids
(SILAC) method (200). More recently, the same method
and its modiﬁed version were used along with microarray
analysis to study the eﬀects of other miRNA mimetics on
the levels of nuclear (201) and whole-cell proteins (202) in
HeLa cells. The analyses have shown that the group of
repressed proteins corresponds well to that of transcripts
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analysis alone may be suﬃcient to reveal the identity
of most of the proteins regulated by miRNAs (203).
The relationships between the cellular levels of speciﬁc
miRNAs, mRNAs and proteins found in these studies
were shown to be functional as the same groups of
transcripts and proteins responded to miRNA inhibition
by speciﬁc antisense LNA oligonucleotide (189). Neither
study considered the problem of cell defense system acti-
vation by miRNA mimetics and inhibitors that were
delivered to cells on diﬀerent carriers and at diﬀerent
concentrations. This aspect therefore needs to be
addressed in further analyses of proteomes perhaps
derived from more immunoresponsive cells than HeLa
treated with the tools of RNAi and miRNA technologies.
The search for further cellular sensors and responders to
foreign RNA using functional genomics and proteomics
approaches and basing on the simple criterion of tran-
script or protein upregulation may not be, however, a
simple task. A recent report shows that the transfections
of numerous diﬀerent miRNAs and siRNAs to cells may
result besides the downregulation of intended and
unintended transcripts also in the upregulation of a
myriad of transcripts that are otherwise suppressed by
endogenous miRNAs in untreated cells (204). Thus, the
overlapping eﬀects of the saturation of cellular RNAi/
miRNA machinery by exogenous RNA reagents and
cell immune responses (both resulting in transcript
upregulation) need to be distinguished. Recent
developments in technology and progress in reading out
the in vivo RNA–RNA and RNA–protein interaction
maps (205) and identifying the RNA recognition
speciﬁcities of various RNA-binding proteins (206) may
speed up the deciphering of the human ribonome code.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
The available information on the sequence non-speciﬁc,
toxic eﬀects of various RNAi reagents strongly
outnumbers the regarding reagents of miRNA technology
(Supplementary Table S1). This disparity is caused at
large by a time delay with which the development of
miRNA technology has begun and by the lower number
of its published applications. In spite of being far from
satisfactory, information on the toxic eﬀects of RNAi
triggers that has been gathered thus far has provided
some useful guidelines on how to use RNAi more specif-
ically and more safely. Much of the successful research has
been focused at unrevealing the sequence and structure
features of RNAi reagents that cause immunostimulation.
Also, chemistry made a substantial contribution in
developing less toxic and more stable reagents by
placing speciﬁc chemical modiﬁcations at well selected
siRNA positions. Less attention has been paid to the
toxic eﬀects of various carriers used to deliver the RNA
reagents to cells. However, the already existing data shows
that the carriers should no longer be considered neutral
delivery vehicles. The number of available RNA carriers is
large and their eﬀects on gene expression need to be more
widely and more carefully analyzed. There are also other
issues relevant to sequence-non-speciﬁc responses that
need to be addressed in further research. These issues
include the need for: clarifying still controversial facts
regarding the immunostimulatory siRNA features,
reducing strong toxic eﬀects caused by genetic vectors
used to express siRNA and miRNA in cells, and a wider
application of functional genomics and proteomics
approaches to ﬁnd new foreign RNA sensors and
responders as well as safer RNA carriers. It would be
also advisable to establish a database of the toxic eﬀects
caused by RNAi and miRNA reagents for which the data
presented in Supplementary Table S1 might serve as an
inspiration. We anticipate that both the RNAi and
miRNA technology will beneﬁt, in the short term, from
more widespread applications of well-designed simple
toxicity tests. Such tests should be dedicated to provide
answers which of the presently known RNA sensors and
immune responders are activated by speciﬁc reagents in
speciﬁc cells and tissues. In the long run, the next gener-
ation of such tests should be developed and based on more
complete information on toxic RNA sensors and
responders gained from transcriptomics and proteomics
approaches.
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